Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters
Miorin et al., bioRxiv, doi:10.1101/2022.02.08.479634 (Preprint)
Miorin et al., The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian.., bioRxiv, doi:10.1101/2022.02.08.479634 (Preprint)
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing that nitazoxanide inhibits SARS-CoV-2 in H9, iAT2, Vero E6, Vero TMPRSS2, and Ace2-A549 cells.
Syrian hamster study showing improvements in SARS-CoV-2 related weight loss, inflammation, viral load, and lung synctia formation with nitazoxanide.
Miorin et al., 9 Feb 2022, preprint, 35 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2022.02.08.479634; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters 2 3 4 5 6 §Lisa Miorin1,2,#, Chad E. Mire3,#, Shahin Ranjbar4,#, 7 Adam J. Hume5,6, Jessie Huang7,8, Nicholas A. Crossland5,9, Kris M White1,2, Manon Laporte1,2, 8 Thomas Kehrer1,2, Viraga Haridas4, Elena Moreno1,2, Aya Nambu4, Sonia Jangra1,2, 9 Anastasija Cupic1,2, Marion Dejosez10, Kristine A. Abo7,8, Anna E. Tseng5,9, 10 Rhiannon B. Werder7,8, Raveen Rathnasinghe1,2, Tinaye Mutetwa1, Irene Ramos1, 11 Julio Sainz de Aja11, Carolina Garcia de Alba Rivas11, Michael Schotsaert1,2, Ronald B. Corley5,9, 12 James V. Falvo4, Ana Fernandez-Sesma1, Carla Kim11,12,13, Jean-François Rossignol14, 13 Andrew A. Wilson7,8, Thomas Zwaka10, Darrell N. Kotton7,8,9, Elke Mühlberger5,6, 14 Adolfo García-Sastre1,2,15,16,17, §Anne E. Goldfeld4,18,19 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 1 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3University of Texas Medical Branch, Galveston, TX, USA; 4Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; 5National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA 6Department of Microbiology, Boston University School of Medicine, Boston, MA, USA; 7Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA; 8The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 9Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA; 10Cell, Developmental & Regenerative Biology, Icahn School of Medicine at Mount Sinai; New York, NY, USA; 11Stem Cell Program, Boston Children’s Hospital, Boston, MA, USA; 12Harvard Stem Cell Institute, Cambridge, Massachusetts; 13Department of Genetics, Harvard Medical School, Boston, MA, USA; 14Romark Institute for Medical Research, Tampa, FL, USA;15Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 16 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 17Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 18Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 19Department of Immunology and Infectious Diseases, Harvard T.C. Chan School of Public Health, Boston, MA, USA. 36 #These authors contributed equally 37 §To whom correspondence should be addressed: 38 Lisa Miorin: lisa.miorin@mssm.edu; Anne E. Goldfeld: anne.goldfeld@childrens.harvard.edu 39 bioRxiv preprint doi: https://doi.org/10.1101/2022.02.08.479634; this version posted February 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 40 Abstract 41 42 A well-tolerated and cost-effective oral drug that..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit